Screener
Tango Therapeutics TNGX Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 7) | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | — | — |
| Stockholders' equity: | ||
| Common stock, $0.001 par value; 400,000,000 and 200,000,000 shares authorized at March 31, 2026 and December 31, 2025, respectively; 144,162,543 and 135,940,454 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 144 | 136 |
| Additional paid-in capital | 1,040,143 | 948,971 |
| Accumulated other comprehensive (loss) income | (115) | 224 |
| Accumulated deficit | (648,666) | (603,152) |
| Total stockholders’ equity | 391,506 | 346,179 |
Item 1. Financial Statements.
FAQ
- What is Tango Therapeutics's common stock?
- Tango Therapeutics (TNGX) reported common stock of 400M in Q1 2026.
- How has Tango Therapeutics's common stock changed year-over-year?
- Tango Therapeutics's common stock increased by 100.0% year-over-year, from 200M to 400M.
- What is the long-term trend for Tango Therapeutics's common stock?
- Over 5 years (2020 to 2025), Tango Therapeutics's common stock has grown at a 449.3% compound annual growth rate (CAGR), from 40K to 200M.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Tango Therapeutics's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude